Cargando…

Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial

BACKGROUND: Probiotics and prebiotics have strain-specific effects on the host. Synbiotics, a mixture of probiotics and prebiotics, are proposed to have more beneficial effects on the host than either agent has alone. PURPOSE: We performed a randomized controlled trial to investigate the effect of L...

Descripción completa

Detalles Bibliográficos
Autores principales: Serce Pehlevan, Ozge, Benzer, Derya, Gursoy, Tugba, Karatekin, Guner, Ovali, Fahri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Pediatric Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303425/
https://www.ncbi.nlm.nih.gov/pubmed/32023397
http://dx.doi.org/10.3345/cep.2019.00381
_version_ 1783548054273523712
author Serce Pehlevan, Ozge
Benzer, Derya
Gursoy, Tugba
Karatekin, Guner
Ovali, Fahri
author_facet Serce Pehlevan, Ozge
Benzer, Derya
Gursoy, Tugba
Karatekin, Guner
Ovali, Fahri
author_sort Serce Pehlevan, Ozge
collection PubMed
description BACKGROUND: Probiotics and prebiotics have strain-specific effects on the host. Synbiotics, a mixture of probiotics and prebiotics, are proposed to have more beneficial effects on the host than either agent has alone. PURPOSE: We performed a randomized controlled trial to investigate the effect of Lactobacillus and Bifidobacterium together with oligosaccharides and lactoferrin on the development of necrotizing enterocolitis (NEC) or sepsis in very low birth weight neonates. METHODS: Neonates with a gestational age ≤32 weeks and birth weight ≤1,500 g were enrolled. The study group received a combination of synbiotics and lactoferrin, whereas the control group received 1 mL of distilled water as placebo starting with the first feed until discharge. The outcome measures were the incidence of NEC stage ≥2 or late-onset cultureproven sepsis and NEC stage ≥2 or death. RESULTS: Mean birth weight and gestational age of the study (n=104) and the control (n=104) groups were 1,197±235 g vs. 1,151±269 g and 29±1.9 vs. 28±2.2 weeks, respectively (P>0.05). Neither the incidence of NEC stage ≥2 or death, nor the incidence of NEC stage ≥2 or late-onset culture-proven sepsis differed between the study and control groups (5.8% vs. 5.9%, P=1; 26% vs. 21.2%, P=0.51). The only significant difference was the incidence of all stages of NEC (1.9% vs. 10.6%, P=0.019). CONCLUSION: The combination of synbiotics and lactoferrin did not reduce NEC severity, sepsis, or mortality.
format Online
Article
Text
id pubmed-7303425
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Pediatric Society
record_format MEDLINE/PubMed
spelling pubmed-73034252020-06-19 Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial Serce Pehlevan, Ozge Benzer, Derya Gursoy, Tugba Karatekin, Guner Ovali, Fahri Clin Exp Pediatr Original Article BACKGROUND: Probiotics and prebiotics have strain-specific effects on the host. Synbiotics, a mixture of probiotics and prebiotics, are proposed to have more beneficial effects on the host than either agent has alone. PURPOSE: We performed a randomized controlled trial to investigate the effect of Lactobacillus and Bifidobacterium together with oligosaccharides and lactoferrin on the development of necrotizing enterocolitis (NEC) or sepsis in very low birth weight neonates. METHODS: Neonates with a gestational age ≤32 weeks and birth weight ≤1,500 g were enrolled. The study group received a combination of synbiotics and lactoferrin, whereas the control group received 1 mL of distilled water as placebo starting with the first feed until discharge. The outcome measures were the incidence of NEC stage ≥2 or late-onset cultureproven sepsis and NEC stage ≥2 or death. RESULTS: Mean birth weight and gestational age of the study (n=104) and the control (n=104) groups were 1,197±235 g vs. 1,151±269 g and 29±1.9 vs. 28±2.2 weeks, respectively (P>0.05). Neither the incidence of NEC stage ≥2 or death, nor the incidence of NEC stage ≥2 or late-onset culture-proven sepsis differed between the study and control groups (5.8% vs. 5.9%, P=1; 26% vs. 21.2%, P=0.51). The only significant difference was the incidence of all stages of NEC (1.9% vs. 10.6%, P=0.019). CONCLUSION: The combination of synbiotics and lactoferrin did not reduce NEC severity, sepsis, or mortality. Korean Pediatric Society 2020-02-05 /pmc/articles/PMC7303425/ /pubmed/32023397 http://dx.doi.org/10.3345/cep.2019.00381 Text en Copyright © 2020 by The Korean Pediatric Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Serce Pehlevan, Ozge
Benzer, Derya
Gursoy, Tugba
Karatekin, Guner
Ovali, Fahri
Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
title Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
title_full Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
title_fullStr Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
title_full_unstemmed Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
title_short Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
title_sort synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303425/
https://www.ncbi.nlm.nih.gov/pubmed/32023397
http://dx.doi.org/10.3345/cep.2019.00381
work_keys_str_mv AT sercepehlevanozge synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial
AT benzerderya synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial
AT gursoytugba synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial
AT karatekinguner synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial
AT ovalifahri synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial